Coegin Pharma hereby announces that the Annual Report for 2024 is available for download on Coegin Pharma's website, http://www.coeginpharma.com/en. The Annual Report is also attached as a PDF to this press release. As previously announced, the Annual General Meeting will be held on 22 May 2025.

2024 marked the beginning of an exciting new phase for Coegin Pharma. The company has laid a solid foundation to become a global player in science-based cosmetic solutions for hair growth and skin pigmentation. The company's innovations are also very well aligned with the beauty-focused side of the longevity megatrend - which is not just about living longer, but about living longer with good health, energy, and wellbeing. With this foundation in place, the company is now preparing for a historic milestone: the launch of the first hair growth product based on Follicopeptide.

With a focus on the global market launch of Follicopeptide, the key activities moving forward are the ongoing production scale-up and partnering activities with key global, regional, and/or commercial partners through business development agreements. Discussions with potential global and regional partners are ongoing.

The auditor's statement regarding the material uncertainty related to the going concern assumption in the auditor's report is based on the fact that Coegin Pharma is a growth company primarily funded through external capital. The Board has also initiated efforts to explore various options for securing new financing. The Board's assessment is that it is likely that measures will be implemented, and that continued liquidity can be secured. Without additional capital, the company is expected to be able to finance its ongoing operations with existing cash at least into the fourth quarter of 2025.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish biotech company primarily focused on peptide-based premium products for hair growth and skin pigmentation. The goal is to commercialise a hair growth product series by the end of 2025, followed by a skin pigmentation product in 2026.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart, and the company has a registered office in Lund, Sweden. 

For more information, please visit: coeginpharma.com/en

Attached files